Online inquiry

IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3766MR)

This product GTTS-WQ3766MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CEACAM6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002483.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4680
UniProt ID P40199
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3766MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10199MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LDP-02
GTTS-WQ11009MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ6532MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ6524MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ7932MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ7005MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ11809MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ4753MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BPS-804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW